GSK injects $293M cash into CureVac, forging a deal to develop new mRNA vaccines and antibodies
GlaxoSmithKline may be playing a supportive role in developing vaccines and treatments for the current pandemic, but it’s angling to take center stage in the next ones.
Messenger RNA is the name of the game, and the pharma giant is throwing its weight behind German biotech player CureVac. A £130m ($163 million) investment buys GSK a roughly 10% stake, while laying down £104m ($130 million) in cash to get an R&D collaboration going. It’s also forking over £26 million ($$32 million) to reserve manufacturing capacity currently under construction.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.